Healthcare insurance in the U.S. can be spotty, even with expansion of coverage under the Affordable Care Act. One of the remaining problem areas is coverage for people who are leaving prison or jail.
Healthcare insurance in the U.S. can be spotty, even with expansion of coverage under the Affordable Care Act. One of the remaining problem areas is coverage for people who are leaving prison or jail. In nonfederal cases, state and county governments pay for healthcare during the period people are incarcerated. But once they are released, there is often a gap before they get signed up for coverage by Medicaid or another payer. For people with chronic health conditions, that gap can lead to medical conditions getting out of control and acute episodes that lead to hospitalization or premature death.
The federal Medicaid Reentry Act of 2021 is designed to remedy the situation. Currently, Medicaid programs are explicitly prohibited from covering incarcerated individuals. The proposed law would permit Medicaid to cover people starting 30 days before they are to be released. Advocates and public health officials say that would mean a smoother transition and increase the chances that recently incarcerated people will receive the medical services they need.
But the Reentry Act could have some unintended consequences. Utsha Khatri, M.D., of the Institute for Heath Equity Research at the Icahn School of Medicine at Mount Sinai in New York and Tyler N.A. Winkelman, M.D., M.Sc., of the Health, Homelessness, and Criminal Justice Lab at the Hennepin Healthcare Research Institute in Minneapolis outlined a few of the consequences in an opinion piece published in April in the New England Journal of Medicine.
Would prisons and jails put off medical care until the 30-day period before release so the cost would fall on a Medicaid program? Would care be substandard? New quality improvements might need to be developed and supported. And the Reentry Act may have little, if any, effect on coverage in the 12 states that haven’t expanded Medicaid, they noted. There are also practical problems of implementing coverage and working with prison and jail officials.
Many people in jail are awaiting trial, incarcerated because they couldn’t afford bail or were denied it. Khatri and Winkelman said they agree with the National Association of Counties and the National Sheriffs’ Association that the Reentry Act should be amended so the ban on Medicaid coverage for incarcerated people would not extend to people in jail who are awaiting trial. They also noted the Reentry Act wouldn’t deal with the larger issue of the harms done by mass incarceration.
In their view, the Reentry Act should be “coupled with broader policies redirecting people away from the harmful carceral system.” In 2021, the Reentry Act was attached to the sweeping Build Back Better legislation that passed in the House but stalled in the Senate. Khatri and Winkelman said Congress may consider the Reentry Act as a separate piece of legislation this year.
Positive Results for Ruxolitinib Cream in Children with Atopic Dermatitis Presented in Ongoing Study
March 18th 2024Ruxolitinib cream showed positive results in children 2- to 11-years-old with mild to moderate atopic dermatitis (AD), according to data of a poster presented at the American Academy of Dermatology Annual Meeting in San Diego from March 8 to 12.
Read More
FDA Updates for Week of March 11: First CAR-T for CLL/SLL and First NASH Treatment
March 16th 2024The FDA this week approved a few firsts: the first treatment for NASH and the first CAR-T cell therapy for CLL/SLL. Other approvals include Tevimbra for esophageal cancer; Livmarli for second liver disease indication; and Praluent for children with genetic form of high cholesterol. The FDA also issued a CRL for monthly MS drug. Additionally, Celltrion submitted an application for an interchangeable Xolair biosimilar.
Read More
A Deep Dive into Predictive and Generative AI with Lynn Carroll of HSBlox
January 3rd 2024In this month’s episode, Briana Contreras, an editor of MHE, chatted with Lynn Carroll, executive of HSBlox, about the difference between predictive and generative AI, yet how each works together in preventive healthcare.
Listen
Transforming the management of genetic testing
March 15th 2024This e-book will explain where the current genetic test management system is inadequate and how a new approach designed specifically for genetic testing will perform better and provide more meaningful and actionable results.
Read More